AR and prostate cancer: Responses to PARPi have been detected in combination with androgen receptor inhibitors in prostate cancer also in patients without obvious mutations causing HR defect in tumors [62], suggesting that blocking AR signaling may induce clinically relevant state of BRCAness to tumors [51].